Dr Rebecca Darlay Professor Heather Cordell Professor Quentin Anstee Professor Ann Daly
| A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation | 2022 |
|
Professor Quentin Anstee
| An international survey on patterns of practice in NAFLD and expectations for therapies—The POP-NEXT project | 2022 |
|
Tim Hicks Dr Will Jones Dr Jana Suklan Professor Quentin Anstee
| Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study | 2022 |
|
Dr Dina Tiniakos Professor Quentin Anstee
| Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD | 2022 |
|
Professor Quentin Anstee
| Derivation and validation of the NAFLD Cirrhosis Score (NCS) to distinguish bridging fibrosis from cirrhosis | 2022 |
|
Helen Jarvis Hannah O'Keefe Professor Dawn Craig Dr Daniel Stow Professor Barbara Hanratty et al. | Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis | 2022 |
|
Professor Quentin Anstee
| Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study | 2022 |
|
Dr Katherine Johnson Dr Peter Leary Dr Olivier Govaere Dr Matthew Barter Sarah Charlton et al. | Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance | 2022 |
|
Dr Marie Boyle Dr Stuart McPherson Professor Arun Sanyal Professor Quentin Anstee
| Letter: non-invasive prediction models to exclude cirrhosis in NAFLD—not everyone fits the mould. Authors' reply | 2022 |
|
Dr Olivier Govaere Dr Rebecca Darlay Dr Julien Peltier Dr Jeremy Palmer Dr Massimo Younes et al. | Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease | 2022 |
|
Dr Olivier Govaere Professor Ann Daly Professor Quentin Anstee
| Metabolic signatures across the full spectrum of nonalcoholic fatty liver disease | 2022 |
|
Professor Quentin Anstee
| Metabolic subtypes of nonalcoholic fatty liver disease patients exhibit distinctive cardiovascular risk profiles | 2022 |
|
Dr Paula Iruzubieta Professor Quentin Anstee
| Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles | 2022 |
|
Professor Quentin Anstee Professor Arun Sanyal
| Noninvasive Evaluation of Response to Obeticholic Acid in Patients with NASH: Results from the REGENERATE Study | 2022 |
|
Professor Quentin Anstee
| Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials | 2022 |
|
Dr Sam Tingle Dr Emily Thompson Lucy Bates Dr Ibrahim Ibrahim Dr Olivier Govaere et al. | Pharmacological testing of therapeutics using normothermic machine perfusion: A pilot study of 2,4-dinitrophenol delivery to steatotic human livers | 2022 |
|
Jadine Scragg Dr Sarah Charman Dr Vincent van Hees Dr Leah Avery Dr Guy Taylor et al. | Physical Activity, Inactivity and Sleep in Patients with Significant Non-Alcoholic Fatty Liver Disease | 2022 |
|
Dr Stuart McPherson Professor Quentin Anstee Dr Kate Hallsworth Helen Jarvis Dr Dina Mansour et al. | Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group | 2022 |
|
Professor Quentin Anstee Dr Kate Hallsworth
| Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions | 2022 |
|
Professor Quentin Anstee
| Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score | 2022 |
|
Professor Quentin Anstee
| A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH | 2021 |
|
Professor Quentin Anstee
| A molecular signature for the metabolic syndrome by urine metabolomics | 2021 |
|
Nardeen Eldafashi Dr Rebecca Darlay Dr Ruchi Shukla Misti McCain Robyn Watson et al. | A pdcd1 role in the genetic predisposition to nafld-hcc? | 2021 |
|
Professor Quentin Anstee
| A Randomized Controlled Trial of the PanPPAR Agonist Lanifibranor in NASH | 2021 |
|
Professor Quentin Anstee
| Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis | 2021 |
|
Dr Massimo Younes Dr Olivier Govaere Dr Dina Tiniakos Professor Alastair Burt Marco Zaki et al. | Caucasian Lean Subjects with Non-Alcoholic Fatty Liver Disease Share Long-Term Prognosis of Non-Lean: Time for Reappraisal of BMI-Driven Approach? | 2021 |
|
Professor Arun Sanyal Professor Quentin Anstee
| Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis | 2021 |
|
Professor Quentin Anstee Professor Arun Sanyal
| Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study | 2021 |
|
Professor Quentin Anstee
| Diagnostic Accuracy of Elastography and Magnetic Resonance Imaging in Patients with NAFLD: a systematic review and meta-analysis | 2021 |
|
Dr Massimo Younes Shilpa Aggarwal Dr Himanshu Garg Professor Quentin Anstee
| Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD – An individual patient data meta-analysis | 2021 |
|
Professor Quentin Anstee
| Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review | 2021 |
|
Dr Kate Hallsworth Dr Stuart McPherson Professor Quentin Anstee Laura Haigh Dr Leah Avery et al. | Digital Intervention with Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults with Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping | 2021 |
|
Dr Dina Mansour Professor Quentin Anstee Dr Stuart McPherson
| Embedding assessment of liver fibrosis into routine diabetic review in primary care | 2021 |
|
Jadine Scragg Dr Kate Hallsworth Guy Taylor Dr Sophie Cassidy Laura Haigh et al. | Factors associated with engagement and adherence to a low energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease | 2021 |
|
Dr Laura Neilson Dr Louise MacDougall Dr Timothy Hardy Dr David Beaton Dr April Phaw et al. | Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease | 2021 |
|
Marco Zaki Dr Ahmed Mahdi Dr Gillian Patman Anna Whitehead Joao Mauricio et al. | Key features of the environment promoting liver cancer in the absence of cirrhosis | 2021 |
|
Dr Jack Leslie Dr Emma Scott Professor Quentin Anstee Professor Fiona Oakley
| Lipid remodelling in hepatocyte proliferation and hepatocellular carcinoma | 2021 |
|
Dr Massimo Younes Dr Olivier Govaere Dr Dina Tiniakos Professor Alastair Burt Marco Youssef William Zaki et al. | Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease | 2021 |
|
Professor Quentin Anstee
| Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests | 2021 |
|
Dr Olivier Govaere Dr Dina Tiniakos Professor Pierre Bedossa Dr Simon Cockell Dr Massimo Younes et al. | NASH limits anti-tumor surveillance in immunotherapy-treated HCC | 2021 |
|
Dr Luca Miele Professor Quentin Anstee Professor Helen Reeves
| Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores | 2021 |
|
Professor Ann Daly Dr Olivier Govaere Professor Quentin Anstee
| Peptide-Based Urinary Monitoring of Fibrotic Non-Alcoholic Steatohepatitis by Mass Barcoded Activity-Based Sensors | 2021 |
|
Professor Quentin Anstee
| Prognostic accuracy of FIB-4, NAFLD fibrosis score, and APRI for NAFLD-related events: a systematic review | 2021 |
|
Professor Quentin Anstee Priyadarshini Basu Dr Pallav Bhatnagar Professor Ann Daly
| rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis | 2021 |
|
Professor Quentin Anstee
| Systematic review with meta-analyses: Diagnostic accuracy of fibrometer tests in patients with non-alcoholic fatty liver disease | 2021 |
|
Professor Quentin Anstee
| Systematic review with meta-analysis: Diagnostic accuracy of Pro-C3 for hepatic fibrosis in patients with non-alcoholic fatty liver disease | 2021 |
|
Professor Quentin Anstee
| The Association of Histologic and Non-invasive Tests with Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis | 2021 |
|
Professor Quentin Anstee
| The European ‘NAFLD Preparedness Index’ — is Europe ready to meet the challenge of fatty liver disease? | 2021 |
|
Dr John Lazarus Professor Quentin Anstee
| The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge? | 2021 |
|
Helen Jarvis Dr Stuart McPherson Professor Quentin Anstee Professor Barbara Hanratty
| The pathway to better primary care for chronic liver disease | 2021 |
|
Dr Olivier Govaere Dr Simon Cockell Professor Ann Daly Professor Quentin Anstee
| Transcriptomics Identify Thrombospondin-2 as a Biomarker for Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis | 2021 |
|
Professor Pierre Bedossa Professor Quentin Anstee Professor Arun Sanyal
| A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study | 2020 |
|
Professor Quentin Anstee
| A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe | 2020 |
|
Professor Arun Sanyal Professor Quentin Anstee
| A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial | 2020 |
|
Professor Quentin Anstee
| Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: a systematic review and meta-analysis | 2020 |
|
Dr Batoul Nasr Professor Quentin Anstee Dr Stuart McPherson
| Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis | 2020 |
|
Dr Olivier Govaere Dr Dina Tiniakos Professor Quentin Anstee Professor Fiona Oakley
| Bone Morphogenic Protein 8B Promotes the Progression of Non-Alcoholic Steatohepatitis | 2020 |
|
Professor Quentin Anstee
| Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design | 2020 |
|
Professor Quentin Anstee
| Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis | 2020 |
|
Dr Olivier Govaere Professor Quentin Anstee
| Erratum: Adverse effects of PD-1 targeted immunotherapy in NAFLD-triggered HCC | 2020 |
|
Dr Matthew Breckons Dr Yemi Oluboyede Professor Luke Vale Dr Laura Ternent Professor Arun Sanyal et al. | Evaluating the patient-perceived impact of non-alcoholic steatohepatitis with compensated cirrhosis | 2020 |
|
Professor Quentin Anstee
| Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes | 2020 |
|
Jadine Scragg Dr Leah Avery Dr Sophie Cassidy Dr Guy Taylor Laura Haigh et al. | Feasibility of a very low calorie diet to achieve a sustainable 10% weight loss in patients with non-alcoholic fatty liver disease | 2020 |
|
Professor Quentin Anstee Professor Pierre Bedossa
| FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study | 2020 |
|
Professor Quentin Anstee Dr Rebecca Darlay Dr Simon Cockell Dr Olivier Govaere Dr Dina Tiniakos et al. | Genome-Wide Association Study of Non-Alcoholic Fatty Liver and Steatohepatitis in a Histologically-Characterised Cohort | 2020 |
|
Dr Lorraine McSweeney Dr Matthew Breckons Dr Gulnar Fattakhova Professor Luke Vale Dr Laura Ternent et al. | Health-Related Quality of Life and Patient-Reported Outcome Measures in NASH-related Cirrhosis | 2020 |
|
Dr Olivier Govaere Professor Quentin Anstee
| Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi∗Z Variant of AAT (Pi∗MZ vs Pi∗ZZ genotype) and Noncarriers | 2020 |
|
Helen Jarvis Professor Dawn Craig Dr Robert Barker Dr Gemma Frances Spiers Dr Daniel Stow et al. | Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population based observational studies | 2020 |
|
Helen Jarvis Hannah O'Keefe Professor Dawn Craig Dr Daniel Stow Professor Quentin Anstee et al. | People with NAFLD also drink alcohol - how should we advise and manage this expanding group in primary care? A systematic review. | 2020 |
|
Dr Massimo Younes Dr Olivier Govaere Dr Dina Tiniakos Professor Alastair Burt Marco Zaki et al. | Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease | 2020 |
|
Dr Massimo Younes Dr Olivier Govaere Dr Luca Miele Dr Dina Tiniakos Professor Alastair Burt et al. | Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease | 2020 |
|
Dr Dina Tiniakos Susan Harrison Professor Quentin Anstee
| qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients with Non-Alcoholic Steatohepatitis | 2020 |
|
Professor Quentin Anstee
| Reply to: “Caveats for the implementation of global strategies against non-alcoholic fatty liver disease” | 2020 |
|
Professor Quentin Anstee
| Reply to: “Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease” | 2020 |
|
Professor Quentin Anstee
| Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis due to NASH: Results from the STELLAR Phase 3 Trials | 2020 |
|
Professor Quentin Anstee
| The Cost of Non-Alcoholic Steatohepatitis (NASH) in Europe and USA: the GAIN Study | 2020 |
|
Dr Timothy Hardy Kristy Wonders Dr Massimo Younes Professor Pierre Bedossa Entesar Betelmal et al. | The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease | 2020 |
|
Professor Quentin Anstee
| The times they are a-changin' (for NAFLD as well) | 2020 |
|
Dr Olivier Govaere Dr Simon Cockell Dr Dina Tiniakos Dr Rachel Queen Dr Massimo Younes et al. | Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis | 2020 |
|
Professor Quentin Anstee Professor Pierre Bedossa
| Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Non-alcoholic Fatty Liver Disease | 2019 |
|
Laura Haigh Dr Dave Houghton Elsbeth Henderson Dr Leah Avery Dr Timothy Hardy et al. | Barriers and Facilitators to Mediterranean Diet Adoption by Patients with Non-alcoholic Fatty Liver Disease in Northern Europe. | 2019 |
|
Professor Quentin Anstee Dr David Price Dr Brendan Payne
| Central obesity and non-alcoholic fatty liver disease in people living with HIV: a case for targeted screening? | 2019 |
|
Dr Federico Ravaioli Professor Quentin Anstee
| Editorial: collagen proportionate area as a prognostic indicator in NAFLD | 2019 |
|
Professor Quentin Anstee Professor Helen Reeves Dr Olivier Govaere
| From NASH to HCC: current concepts and future challenges | 2019 |
|
Dr Marie Boyle Kate Hallsworth Dr Dina Tiniakos Professor Quentin Anstee
| Health-related Quality of Life in Non-alcoholic Fatty Liver Disease Associates With Hepatic Inflammation. | 2019 |
|
Professor Quentin Anstee
| Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials | 2019 |
|
Professor Quentin Anstee Professor Pierre Bedossa Professor Arun Sanyal
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial | 2019 |
|
Dr Marie Boyle Dr Dina Tiniakos Dr Olivier Govaere Dr Massimo Younes Dr Stuart McPherson et al. | Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease | 2019 |
|
Professor Arun Sanyal Professor Quentin Anstee Professor Pierre Bedossa
| REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis | 2019 |
|
Professor Arun Sanyal Professor Quentin Anstee
| Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD | 2019 |
|
Dr Dave Houghton Dr Kate Hallsworth Dr Sophie Cassidy Christian Thoma Dr Leah Avery et al. | The degree of hepatic steatosis associates with impaired cardiac and autonomic function | 2019 |
|
Dr Kate Hallsworth Dr Stephan Dombrowski Dr Stuart McPherson Professor Quentin Anstee Dr Leah Avery et al. | Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study | 2019 |
|
Professor Loranne Agius Professor Quentin Anstee
| Application of long single-stranded DNA donors in genome editing: Generation and validation of mouse mutants | 2018 |
|
Professor Loranne Agius Professor Quentin Anstee
| Application of long single-stranded DNA donors in genome editing: generation and validation of mouse mutants | 2018 |
|
Dr John Brain Professor Alastair Burt Professor Quentin Anstee
| Author correction: Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity | 2018 |
|
Professor Quentin Anstee
| Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science | 2018 |
|
Dr Marie Boyle Professor Quentin Anstee
| Editorial: hepatocellular carcinoma in non-cirrhotic NASH - a troubling reality | 2018 |
|
Dr John Brain Professor Quentin Anstee
| Erratum to: Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity (Nature, (2017), 551, 7680, (340-345), 10.1038/nature24302) | 2018 |
|
Professor Quentin Anstee
| European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale. | 2018 |
|
Dr Dina Tiniakos Professor Quentin Anstee Professor Alastair Burt
| Fatty Liver Disease | 2018 |
|
Emma Scott Professor Quentin Anstee
| Genetics of alcoholic liver disease and non-alcoholic steatohepatitis | 2018 |
|
Professor Quentin Anstee Dr Timothy Hardy
| Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention | 2018 |
|
Professor Quentin Anstee Professor Chris Day Professor Arun Sanyal
| Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030 | 2018 |
|
Professor Quentin Anstee
| Noninvasive Prediction of Esophageal Varices by Stiffness and Platelet in Nonalcoholic Fatty Liver Disease Cirrhosis | 2018 |
|
Professor Quentin Anstee
| Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany | 2018 |
|
Professor Quentin Anstee
| Rifaximin in non-alcoholic steatohepatitis: An open-label pilot study | 2018 |
|
Professor Quentin Anstee
| Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease | 2018 |
|
Dr Marie Boyle Dr Steven Masson Professor Quentin Anstee
| The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease | 2018 |
|
Dr Emma Scott Professor Quentin Anstee
| The genetics of alcoholic liver disease and non-alcoholic steatohepatitis | 2018 |
|
Dr Olivier Govaere Professor Quentin Anstee
| Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis | 2018 |
|
Professor Quentin Anstee
| Thrombin and factor Xa link the coagulation system with liver fibrosis | 2018 |
|
Dr Stuart McPherson Dr Nina Wilson Dr Dina Tiniakos Dr Jennifer Wilkinson Professor Alastair Burt et al. | A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis | 2017 |
|
Dr Stuart McPherson Dr Timothy Hardy Dr Dina Tiniakos Professor Alastair Burt Professor Chris Day et al. | Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis | 2017 |
|
Dr Dave Houghton Dr Sophie Cassidy Dr Christian Thoma Dr Kate Hallsworth Dr Leah Avery et al. | Autonomic function is impaired across the spectrum of NAFLD | 2017 |
|
Professor Quentin Anstee Professor Arun Sanyal
| Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum | 2017 |
|
Dr David Sheridan Professor Quentin Anstee Dr Stuart McPherson
| Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey | 2017 |
|
Dr Mikolaj Ogrodnik Dr Satomi Miwa Dr Dina Tiniakos Dr Caroline Wilson Professor Chris Day et al. | Cellular senescence drives age-dependent hepatic steatosis | 2017 |
|
Dr Dave Houghton Dr Kate Hallsworth Dr Christian Thoma Dr Sophie Cassidy Dr Timothy Hardy et al. | Effects of Exercise on Liver Fat and Metabolism in Alcohol Drinkers | 2017 |
|
Dr Dave Houghton Christian Thoma Dr Kate Hallsworth Dr Sophie Cassidy Dr Timothy Hardy et al. | Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial | 2017 |
|
Professor Quentin Anstee
| Genetic variation in GABRβ1 and the risk for developing alcohol dependence | 2017 |
|
Dr Emma Scott Dr Jeremy Palmer Professor Quentin Anstee
| Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD | 2017 |
|
Dr John Brain Professor Alastair Burt Professor Quentin Anstee
| Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity | 2017 |
|
Dr Leah Avery Professor Catherine Exley Dr Stuart McPherson Professor Mike Trenell Professor Quentin Anstee et al. | Lifestyle Behavior Change in Patients With Nonalcoholic Fatty Liver Disease: A Qualitative Study of Clinical Practice | 2017 |
|
Misti McCain Dr Luca Miele Dr Paula Iruzubieta Professor Helen Reeves Professor Quentin Anstee et al. | MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals | 2017 |
|
Professor Quentin Anstee
| NAFLD: PNPLA3 and obesity: a synergistic relationship in NAFLD | 2017 |
|
Professor Quentin Anstee
| Non-Alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases | 2017 |
|
Dr Timothy Hardy Dr Mujdat Zeybel Professor Chris Day Dr Christian Dipper Dr Steven Masson et al. | Plasma DNA methylation: A potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease | 2017 |
|
Dr Lucy Walker Professor Ann Daly Dr Luca Miele Professor Quentin Anstee Professor Helen Reeves et al. | Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease | 2017 |
|
Dr Olivier Govaere Professor Quentin Anstee
| The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma | 2017 |
|
Professor Quentin Anstee Dr Yang-Lin Liu Dr Rebecca Darlay Professor Heather Cordell Professor Ann Daly et al. | Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans | 2017 |
|
Professor Quentin Anstee
| Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study | 2017 |
|
Professor Quentin Anstee
| A fatty liver leads to a broken heart? | 2016 |
|
Professor Quentin Anstee Professor Arun Sanyal
| ALT as a non-invasive biomarker of histological response to pharmacotherapy in NASH patients: insights from the elafibranor GOLDEN505 trial | 2016 |
|
Dr Stuart McPherson Professor Quentin Anstee
| Changing Epidemiology of Chronic Liver Disease Among Ethnic Groups in the United States | 2016 |
|
Dr Dina Tiniakos Professor Quentin Anstee Professor Chris Day Professor Alastair Burt Dr John Brain et al. | Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference | 2016 |
|
Professor Quentin Anstee
| Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening | 2016 |
|
Dr Dave Houghton Dr Sophie Cassidy Dr Kate Hallsworth Dr Kieren Hollingsworth Professor Roy Taylor et al. | Exercise reduces liver fat and improves body composition but not insulin sensitivity or inflammatory markers in non-alcoholic steatohepatitis | 2016 |
|
Professor Quentin Anstee Professor Chris Day
| Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease | 2016 |
|
Dr Nimantha de Alwis Professor Quentin Anstee Professor Chris Day
| How to Diagnose Nonalcoholic Fatty Liver Disease | 2016 |
|
Professor Quentin Anstee Professor Arun Sanyal
| Improvement in NASH histological activity highly correlates with fibrosis regression | 2016 |
|
Dr Timothy Hardy Professor Fiona Oakley Professor Quentin Anstee Professor Chris Day
| Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum | 2016 |
|
Professor Quentin Anstee
| Novel Fibroscan-Based Score to Diagnose NASH and its severity in A Multi-centre UK Cohort of Patients with Suspected NAFLD | 2016 |
|
Professor Quentin Anstee
| Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis | 2016 |
|
Professor Quentin Anstee Dr David Sheridan
| Staging fibrosis and excluding advanced fibrosis in patients with NAFLD: comparison of non-invasive markers in an interim analysis from a prospective multicentre study | 2016 |
|
Professor Quentin Anstee Professor Arun Sanyal
| Validation of mir-34a, mir-122 and mir-200a as bio-markers for identification of NASH patients eligible for treatment | 2016 |
|
Professor Quentin Anstee
| An overview of the genetics, mechanisms and management of NAFLD and ALD | 2015 |
|
Professor Quentin Anstee
| An overview of the genetics, mechanisms and management of NAFLD and ALD | 2015 |
|
Dr Mujdat Zeybel Dr Timothy Hardy Stuart Robinson Christopher Fox Professor Quentin Anstee et al. | Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease | 2015 |
|
Anna Whitehead Dr Gillian Patman Professor Chris Day Dr Dina Tiniakos Professor Quentin Anstee et al. | Effects of FXR agonist PX20606 on tumour formation in animal models of non-alcoholic fatty liver disease | 2015 |
|
Dr Stuart McPherson Dr Timothy Hardy Elsbeth Henderson Professor Alastair Burt Professor Chris Day et al. | Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management | 2015 |
|
Dr Dave Houghton Dr Christian Thoma Dr Kate Hallsworth Dr Kieren Hollingsworth Professor Chris Day et al. | Exercise reduces liver fat, visceral fat and circulating triglycerides, but not circulating inflammatory markers in non-alcoholic steatohepatitis | 2015 |
|
Professor Quentin Anstee Professor Ann Daly Professor Chris Day
| Genetics of Alcoholic Liver Disease | 2015 |
|
Dr Stuart McPherson Dr Timothy Hardy Professor Alastair Burt Professor Chris Day Professor Quentin Anstee et al. | High rate of false positives for advanced fibrosis when simple non-invasive fibrosis tests are used in older patients (>=65 years) with NAFLD | 2015 |
|
Dr Timothy Hardy Victoria Sharkey Dr Mujdat Zeybel Professor John Mathers Steven White et al. | Laser capture microdissection reveals cell-specific DNA methylation signatures in key fibrosis modifier genes in chronic liver disease | 2015 |
|
Dr Jeremy Palmer Dr Yang-Lin Liu Professor Chris Day Professor Ann Daly Professor Quentin Anstee et al. | Mechanistic Study of TM6SF2 in NAFLD pathogenesis: Stably transfected Huh7 cells over-expressing the TM6SF2 E167K variant exhibit greater levels of oxidative stress | 2015 |
|
Dr Kate Hallsworth Christian Thoma Dr Kieren Hollingsworth Dr Sophie Cassidy Professor Quentin Anstee et al. | Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: A randomised controlled trial | 2015 |
|
Dr Jess Dyson Professor Quentin Anstee Dr Stuart McPherson
| Non-alcoholic fatty liver disease: a practical approach to treatment | 2015 |
|
Professor Chris Day Professor Quentin Anstee
| Nonalcoholic Fatty Liver Disease: Foreword | 2015 |
|
Dr Timothy Hardy Professor Quentin Anstee Professor Chris Day
| Nonalcoholic fatty liver disease: new treatments | 2015 |
|
Anna Whitehead Laura Ogle Dr Gillian Patman Dr Ali Anwar Dr Dina Tiniakos et al. | Ras and p-ERK in metabolic syndrome associated Hepatocellular Carcinoma (HCC) | 2015 |
|
Professor Quentin Anstee Dr Yang-Lin Liu Professor Chris Day Professor Helen Reeves
| Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance | 2015 |
|
Professor Helen Reeves Dr Luca Miele Professor Quentin Anstee
| Telomerase reverse transcriptase mutations are associated with hepatocellular carcinoma in nash | 2015 |
|
Rodolphe Anty Professor Chris Day Professor Ann Daly Anh Tran Professor Quentin Anstee et al. | The FNDC5 rs3480 is protective on the steatosis and fibrosis in patients with NAFLD | 2015 |
|
Professor Quentin Anstee Professor Chris Day
| The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2 | 2015 |
|
Professor Quentin Anstee
| The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicity | 2015 |
|
Professor Ann Daly Professor Chris Day Dr Yang-Lin Liu Professor Quentin Anstee
| TM6SF2 as a Genetic Risk Factor for Fibrosis | 2015 |
|
Dr Yang-Lin Liu Professor Ann Daly Professor Chris Day Professor Quentin Anstee
| TM6SF2: Catch-22 in the Fight Against Nonalcoholic Fatty Liver Disease and Cardiovascular Disease? | 2015 |
|
Professor Quentin Anstee Professor Chris Day
| Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis | 2015 |
|
Dr Stuart McPherson Professor Quentin Anstee
| Wafarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C): results at one year | 2015 |
|
Dr Yang-Lin Liu Dr Gillian Patman Julian Leathart Professor Alastair Burt Professor Chris Day et al. | Carriage of the PNPLA3 rs738409 C>G Polymorphism Confers an Increased Risk of Non-Alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma | 2014 |
|
Dr Mujdat Zeybel Dr Timothy Hardy Christopher Fox Dr Steven Masson Professor Derek Mann et al. | Differential DNA methylation of genes involved in fibrosis progression in NAFLD and ALD | 2014 |
|
Julian Leathart Professor Ann Daly Professor Chris Day Professor Quentin Anstee
| Gene Polymorphisms of Cellular Senescence Marker P21 and Disease Progression in Non-Alcohol-Related Fatty Liver Disease | 2014 |
|
Professor Quentin Anstee
| Liver and Biliary Tract Disease | 2014 |
|
Rodolphe Anty Professor Quentin Anstee
| Low Levels of 25-Hydroxy Vitamin D are Independently Associated with the Risk of Bacterial Infection in Cirrhotic Patients | 2014 |
|
Dr Stuart McPherson Elsbeth Henderson Dr Timothy Hardy Professor Alastair Burt Professor Chris Day et al. | Natural history of NAFLD: A study of 108 patients with paired liver biopsies | 2014 |
|
Dr Stuart McPherson Dr Timothy Hardy Professor Alastair Burt Professor Chris Day Professor Quentin Anstee et al. | Natural History of NAFLD: A Study of 108 Patients with Paired Liver Biopsies | 2014 |
|
Dr Kate Hallsworth Dr Christian Thoma Sarah Moore Dr Thomas Ploetz Professor Quentin Anstee et al. | Non-alcoholic fatty liver disease is associated with higher levels of objectively measured sedentary behaviour and lower levels of physical activity than matched healthy controls | 2014 |
|
Dr Jess Dyson Dr Stuart McPherson Professor Quentin Anstee
| Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification | 2014 |
|
Rodolphe Anty Professor Quentin Anstee
| Prophylaxis of bacterial infections in cirrhosis: Is an optimal 25-OH vitamin D level required? | 2014 |
|
Professor Quentin Anstee Dr Mark Hudson Professor Helen Reeves
| Reply to "Hepatocellular carcinoma and the Newcastle-upon-Tyne area" | 2014 |
|
Dr Stuart McPherson Elsbeth Henderson Professor Alastair Burt Professor Chris Day Professor Quentin Anstee et al. | Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease | 2014 |
|
Dr Yang-Lin Liu Professor Helen Reeves Professor Alastair Burt Dr Dina Tiniakos Dr Stuart McPherson et al. | TM6SF2 rs58542926 Influences Hepatic Fibrosis Progression in Patients with Non-Alcoholic Fatty Liver Disease | 2014 |
|
Professor Quentin Anstee Dr Rebecca Darlay Julian Leathart Yilei Liu Professor Alastair Burt et al. | A candidate-gene approach to validation of genetic modifier associations using a large cohort with histologically characterised non-alcoholic fatty liver disease | 2013 |
|
Anna Whitehead Dr Gillian Patman Liam Cornell Dr Despina Televantou Professor Nicola Curtin et al. | A Role for DNA Repair Protein Kinase (DNA-PK) in the Progression of Simple Steatosis to Steatohepatitis (NASH)? | 2013 |
|
Dr Stuart McPherson Professor Quentin Anstee Professor Chris Day Professor Alastair Burt
| Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? | 2013 |
|
Dr Kate Hallsworth Dr Kieren Hollingsworth Dr Christian Thoma Professor Djordje Jakovljevic Dr Guy MacGowan et al. | Cardiac function improves following high intensity intermittent exercise in adults with non-alcoholic fatty liver disease | 2013 |
|
Dr Kate Hallsworth Dr Kieren Hollingsworth Dr Christian Thoma Professor Djordje Jakovljevic Dr Guy MacGowan et al. | Cardiac function improves following high intensity intermittent exercise in adults with non-alcoholic fatty liver disease | 2013 |
|
Dr Kate Hallsworth Dr Kieren Hollingsworth Dr Christian Thoma Professor Quentin Anstee Professor Chris Day et al. | Cardiac Function Improves Following High Intensity Intermittent Exercise Therapy in Non-Alcoholic Fatty Liver Disease | 2013 |
|
Dr Kate Hallsworth Dr Kieren Hollingsworth Dr Christian Thoma Professor Djordje Jakovljevic Dr Guy MacGowan et al. | Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease | 2013 |
|
Dr Yang-Lin LIU Dr Gillian Patman Julian Leathart Professor Alastair Burt Professor Chris Day et al. | Carriage of PNPLA3 I148M is Associated with an Increased Risk of Non-Alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma | 2013 |
|
Professor Quentin Anstee Dr Steven Masson Dr Stuart McPherson
| Does the Pre-Bone Mineral Density Frax Score Predict Fracture Risk in Patients with Cirrhosis? | 2013 |
|
Professor Quentin Anstee
| Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment | 2013 |
|
Dr Kate Hallsworth Dr Christian Thoma Professor Quentin Anstee Professor Chris Day Professor Mike Trenell et al. | Higher Objectively Measured Sedentary Behaviour and Lower Levels of Physical Activity than Matched Healthy Controls | 2013 |
|
Dr Christian Thoma Dr Kate Hallsworth Dr Kieren Hollingsworth Professor Quentin Anstee Professor Chris Day et al. | HIGH-INTENSITY INTERMITTENT EXERCISE THERAPY REDUCES LIVER FAT AND IMPROVES BODY COMPOSITION IN ADULTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE | 2013 |
|
Professor Quentin Anstee Dr Yang-Lin Liu Professor Heather Cordell Dr Rebecca Darlay Professor Chris Day et al. | Mapping Expression Quantitative Traits Loci (EQTL) for PNPLA3 Gene Identifies Additional SNPs Associated with Non-Alcoholic Fatty Liver Disease (NAFLD) Independent of rs738409 | 2013 |
|
Dr Gillian Patman Dr Despina Televantou Anna Whitehead Professor Chris Day Professor Fiona Oakley et al. | Mild Steatosis and Impaired Glucose Tolerance are Associated with Liver Cancer Development, While Progression to Nash Increases Number/Size in an Animal Model of NAFLD | 2013 |
|
Professor Quentin Anstee
| Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in mice | 2013 |
|
Professor Quentin Anstee
| Mutations in the Gabrb1 gene promote alcohol consumption through increased tonic inhibition | 2013 |
|
Dr Jess Dyson Dr Stuart McPherson Professor Quentin Anstee
| Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification | 2013 |
|
Professor Quentin Anstee Professor Chris Day
| Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis | 2013 |
|
Professor Quentin Anstee
| Rifaximin in Non-Alcoholic Steatohepatitis an Open-Label Pilot Study | 2013 |
|
Professor Quentin Anstee
| Rifaximin in Non-Alcoholic Steatohepatitis: An Open-Label Pilot Study | 2013 |
|
Professor Quentin Anstee Professor Chris Day
| The genetics of NAFLD | 2013 |
|
Professor Quentin Anstee Professor Chris Day
| S-adenosylmethionine (SAMe) therapy in liver disease: A review of current evidence and clinical utility | 2012 |
|
Professor Quentin Anstee Professor Chris Day
| A lipid to treat non-alcoholic fatty liver disease – The dawn of ‘lipo-rehabilitation’? | 2012 |
|
Professor Quentin Anstee
| A role for anticoagulation in fibrogenesis: Supression of human hepatic stellate cell contractility and liver fibrosis in vitro and vivo | 2012 |
|
Professor Quentin Anstee Dr Rebecca Darlay Julian Leathart Professor Helen Reeves Professor Alastair Burt et al. | Genome-Wide Association Analysis Confirms Importance of PNPLA3 and Identifies Novel Variants Associated With Histologically Progressive Steatohepatitis in NAFLD | 2012 |
|
Professor Quentin Anstee
| H-1-NMR metabolic profiling in germ-free and conventionally housed mouse models of acetaminophen-induced hepatotoxicity | 2012 |
|
Dr Gillian Patman Douglas Hui Professor Quentin Anstee Professor Helen Reeves
| Kruppel-like factor 6 splice variant 3 (KLF6-SV3) - The redox sensitive splice variant of KLF6 expressed in non-alcoholic steatohepatitis (NASH) | 2012 |
|
Professor Quentin Anstee
| Measuring the effectiveness of a multidisciplinary non-alcoholic fatty liver disease clinic | 2012 |
|
Dr Mujdat Zeybel Dr Timothy Hardy Frances Wong Professor John Mathers Christopher Fox et al. | Multigenerational epigenetic adaptation of the hepatic wound-healing response | 2012 |
|
Dr Gillian Patman Douglas Hui Professor Quentin Anstee Professor Helen Reeves
| Oxidative stress induces alternative splicing and nuclear translocation of kruppel like factor 6 | 2012 |
|
Professor Quentin Anstee
| Quantifying hepatic steatosis - more than meets the eye | 2012 |
|
Professor Quentin Anstee
| Targeted inhibition of tissue factor and thrombin on CD31 expressing cells suppresses hepatic fibrosis in CCl4 treated mice | 2012 |
|
Professor Quentin Anstee
| Targeted inhibition of tissue factor and thrombin on CD31 expressing cells supresses hepatic fibrosis in CCL4 treated mice | 2012 |
|
Professor Quentin Anstee
| Targeted inhibition of Tissue Factor suppresses hepatic fibrosis in CCL4 treated mice | 2012 |
|
Ahmad Alserri Professor Quentin Anstee Julian Leathart Julia Patch Professor Chris Day et al. | The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies | 2012 |
|
Dr Stuart McPherson Dr Timothy Hardy Professor Alastair Burt Professor Chris Day Professor Quentin Anstee et al. | The FIB-4 score reliability excludes advanced fibrosis in a diabetic cohort with NAFLD | 2012 |
|
Professor Quentin Anstee
| A novel mouse model of hepatic glycogen storage disease Type 3 identified using a phenotype-driven ethyl-nitrosourea (ENU) mutagensis screen | 2011 |
|
Professor Quentin Anstee
| Activating Autophagocytosis Decreases Fat Within the Liver | 2011 |
|
Professor Quentin Anstee
| Animal models in nonalcoholic steatohepatitis research: utility and clinical translation | 2011 |
|
Dr Stuart McPherson Professor Quentin Anstee Elsbeth Henderson Professor Alastair Burt Professor Chris Day et al. | Are simple non-invasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? | 2011 |
|
Professor Quentin Anstee Professor Ann Daly Professor Chris Day
| Genetic modifiers of non-alcoholic fatty liver disease progression | 2011 |
|
Professor Quentin Anstee Professor Ann Daly Professor Chris Day
| Genetics of alcoholic liver disease and nonalcoholic fatty liver disease | 2011 |
|
Dr Gillian Patman Professor Quentin Anstee Professor Helen Reeves
| Hepatocellular Carcinoma in NASH: Is there a biological Rationale? | 2011 |
|
Professor Quentin Anstee Dr Stuart McPherson Professor Chris Day
| How big a problem is non-alcoholic fatty liver disease? | 2011 |
|
Professor Quentin Anstee
| Hypercoagulability in cirrhosis: causes and consequences | 2011 |
|
Professor Quentin Anstee
| Multi-Excitation Fluorescence Spectroscopy for Analysis of Non-Alcoholic Fatty Liver Disease | 2011 |
|
Professor Quentin Anstee
| The role of hypercoagulability in liver fibrogenesis | 2011 |
|
Professor Quentin Anstee
| Vanin-1 activity modulates the steatosis-steatohepatitis transition in progressive non-alcoholic steatohepatitis | 2011 |
|
Professor Quentin Anstee
| Cell surface pantetheinase, Vanin-1, increases oxidative damage in acetaminophen-induced liver injury via a reduction in glutathione | 2010 |
|
Professor Quentin Anstee
| Coagulation proteins in acute liver injury: a role in initiation and propagation | 2010 |
|
Professor Quentin Anstee Brian Smith
| Hepatitis B and hepatitis C co-infection | 2010 |
|
Professor Quentin Anstee
| Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis | 2010 |
|
Professor Quentin Anstee
| Is oil red-O and digital image analysis the gold standard for quantifying steatosis in the liver? | 2010 |
|
Professor Quentin Anstee
| Is oil red-O staining and digital image analysis the gold standard for quantifying steatosis in the liver? | 2010 |
|
Professor Quentin Anstee
| Novel quantitative trait locus for acetaminophen-induced hepatotoxicty identified on chromosome 18 | 2010 |
|
Professor Quentin Anstee
| Rational Testing: Investigating mildly abnormal serum aminotransferase values | 2010 |
|
Professor Quentin Anstee
| Role of monocytes and macrophages in experimental and human acute liver failure | 2010 |
|
Professor Quentin Anstee
| A missense mutation in the non-neural G-protein α-subunit isoforms modulates susceptibility to obesity | 2009 |
|
Professor Quentin Anstee
| Autofluorescence: modelling a tool for assessment of steatotic marginal grafts in liver transplantation | 2009 |
|
Professor Quentin Anstee Professor Matthew Wright
| Parenchymal extinction: coagulation and hepatic fibrogenesis | 2009 |
|
Professor Quentin Anstee
| Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue | 2009 |
|
Professor Quentin Anstee
| The importance of fatty liver disease in clinical practice | 2009 |
|
Professor Quentin Anstee Professor Matthew Wright
| Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies | 2008 |
|
Professor Quentin Anstee
| Effect of a thrombin receptor (protease-activated receptor 1, PAR-1) gene polymorphism in chronic hepatitis C liver fibrosis | 2008 |
|
Professor Quentin Anstee
| Hypercoagulation and thrombophilia in liver disease | 2008 |
|
Professor Quentin Anstee
| Identification of a model of alcohol preference and its similarity to human alcoholism | 2008 |
|
Professor Quentin Anstee
| Can disease progression in non-alcoholic fatty liver disease be predicted by metabolic biomarkers of lipid accumulation and peroxidation? | 2007 |
|
Professor Quentin Anstee
| Dietary constituents in mice are reflected in the hepatic lipid profile as detected by carbon-13 magic angle spinning magnetic resonance spectroscopy | 2007 |
|
Professor Quentin Anstee
| Microarray analysis demonstrates insulin resistance is central to NASH pathogenesis in the IGT/6 model and suggests a role for CEACAM-1 in disease pathogenesis | 2007 |
|
Professor Quentin Anstee
| Microarray principal components analysis demonstrates expression of Vanin-1 is a strong determinant of NASH pathogenesis in the IGT/6 model | 2006 |
|
Professor Quentin Anstee
| Mouse models in non-alcoholic fatty liver disease and steatohepatitis research | 2006 |
|
Professor Quentin Anstee Professor Matthew Wright
| The factor V Leiden mutation accelerates disease progression in a mouse model of hepatic fibrosis induced by chronic carbon tetrachloride exposure | 2004 |
|
Professor Quentin Anstee
| A novel murine model of non-alcoholic steatohepatitis generated using a sensitised ENU mutagenesis screen | 2003 |
|
Professor Quentin Anstee
| The safe use of percutaneous gastrostomy for enteral nutrition in patients with Crohn's disease | 2000 |
|
Professor Quentin Anstee
| [Abstract] Safety of percutaneous gastrostomy (PEG) feeding in Crohn's disease | 1999 |
|
Professor Quentin Anstee
| [Abstract] Safety of percutaneous gastrostomy (PEG) feeding in Crohn's disease | 1999 |
|
Professor Quentin Anstee
| Vectorial function of major histocompatibility complex class II in a human intestinal cell line | 1999 |
|